Danish Genmab A/S has received the SCRIP Biotech Company of the Year award.

The SCRIP awards celebrate the achievements of the international biopharmaceutical industry and were presented at an awards ceremony in London.

“We are deeply honored to receive the Biotech Company of the Year award for the impressive advances we’ve made with our pipeline, proprietary innovative technology platforms, partnerships and financial security. This award recognizes the company’s recent transformation and is a testament to the tireless determination of all Genmab employees,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The Biotech of the Year award is given to the company who has achieved the most in terms of becoming a more mature company, signing a transformative deal or raising new funds and recognizes Genmab’s numerous accomplishments during 2012 & 2013 including entering three major licensing agreements and making significant progress with the ofatumumab and daratumumab programs, as stated in the company’s press release.